Dexmedetomidine Versus Placebo in Endoscopic Retrograde

Status Completed

Clinical Trial Summary

In this pilot prospective non-commercial clinical trial the investigators will study the use of dexmedetomidine as an adjuvant to the patient-controlled propofol sedation in a placebo-controlled and randomized manner in patients with drug addiction during Endoscopic Retrograde Cholangiopancreatography (ERCP). Dexmedetomidine is a sedative medication used mostly in intensive care units,and is marketed under the brand name Precedex. Dexmedetomidine has sedative, analgesic, sympatholytic, and anxiolytic properties. It produces sedation without causing significant respiratory depression. Recent research has suggested dexmedetomidine to be effective in treatment of alcohol withdrawal signs. In previous studies dexmedetomidine was insufficient as an only sedative agent in ERCP and colonoscopy, but it has not been assessed for sedation in patients with chronic pancreatitis. The main objective of this trial is to evaluate if dexmedetomidine can reduce propofol and opioid consumption and facilitate the performance of ERCP in patients with chronic pancreatitis due to drug addiction.Secondary objectives of the trial are the stability of vital signs and safety, patients´ satisfaction plus recovery time from sedation.

50 elective ERCP patients with chronic pancreatitis after written informed consent and randomisation will be recruited to the study. Exclusion criteria are:allergy to propofol, opioid or dexmedetomidine, ASA class greater than 3. All the patients will receive patient-controlled propofol sedation. In dexmedetomidine group dexmedetomidine infusion will be started before sedation beginning and in placebo group placebo-solution (NaCl0,9%) will be administered in the similar manner.Standard monitoring for vital signs will be applied,also sedation degrees will be evaluated with sedation scores. At the end of procedure total amount of propofol and opioid will be calculated,patients and endoscopists satisfaction and the difficulty of ERCP will be assessed.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Pancreatitis

Clinical Trial Details

NCT number	NCT01070680
Study type	Interventional
Source	Helsinki University Central Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	March 2010
Completion date	January 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03609944` - SpHincterotomy for Acute Recurrent Pancreatitis	N/A
Not yet recruiting	`NCT04652271` - International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
Completed	`NCT01441492` - Pancreas Resection With and Without Drains	N/A
Recruiting	`NCT02196935` - Los Angeles Prospective GI Biliary and EUS Series
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Completed	`NCT01545167` - The North American Pancreatitis Study	N/A
Completed	`NCT04168801` - Early Oral Refeeding in Mild Acute Pancreatitis	N/A
Recruiting	`NCT03334708` - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Completed	`NCT01824186` - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy	N/A
Terminated	`NCT00428025` - Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients	Phase 4
Completed	`NCT00639314` - Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy	N/A
Recruiting	`NCT00160836` - Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter	Phase 1
Completed	`NCT00121901` - Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?	Phase 3
Completed	`NCT00999232` - Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube	Phase 4
Terminated	`NCT00419549` - Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)	Phase 2/Phase 3
Active, not recruiting	`NCT05095831` - EUS Shear Wave for Solid Pancreatic Lesions.
Completed	`NCT03601325` - Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
Not yet recruiting	`NCT06133023` - WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts	N/A
Withdrawn	`NCT02465138` - A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis	Phase 4
Recruiting	`NCT02971475` - ESWL Versus ESWL and Endoscopic Treatment	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms